GT
Goldenrod Therapeutics, Inc.
SEC filingBiotechnology · Houston, TX
Amount raised$3.2Msold at filing
Total offering$6.5M$3.3M still open
Investors in the raise2count reported to the SEC
FiledJun 3, 2026first sale May 26, 2026
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Dev ChatterjeeExecutive Officer
Leo Linbeck IVExecutive Officer
Mark WorschehExecutive Officer, Director
Atul VaradhacharyExecutive Officer, Director
Leo Linbeck IIIDirector
Thomas BrenninkmeijerDirector
Executive officers, directors and promoters as listed on the Form D.